Beyond the corner of happy and healthy
Walgreens is no longer at the corner of happy and healthy. It’s expanded well beyond the U.S. neighborhood and, while it’s not everywhere yet, it’s bigger than anyone else. A lot bigger. This size creates challenges for the U.S. OTC market.
The growth of Walgreens Boots Alliance, Walgreens’ parent company, has major implications for U.S. brand owners. Walgreens Boots Alliance is growing through acquisition. In their own words, Walgreens is part of “the first global, pharmacy-led health and wellbeing enterprise.” And it’s still getting bigger. When — probably not “if” — the Rite Aid deal is closed, the leading position in the United States will be clearly cemented.
There are a lot more corners and parts to the new organization. Walgreen’s has more than 8,000 stores in the United States and now is a division of a global drug chain of more than 13,200 stores in 11 countries. WBA also is one of the largest global pharmaceutical wholesalers with more than 390 distribution centers delivering to more than 230,000 pharmacies in more than 20 countries, ranging from Boots in the United Kingdom, Thailand, Norway, the Republic of Ireland and the Netherlands, Benavides in Mexico and Ahumada in Chile. Walgreens also is part of a store brand powerhouse with No7, Boots Pharmaceuticals, Botanics, Liz Earle and Soap & Glory, among others.
The implications of WBA’s global growth are important. When you combine merger-and-acquisition-inspired borrowed money pressuring cash flow, a far better global view of wholesale prices, strong focused store brands, rationalized retail portfolios, tougher margin requirements and institutionalized increased trade promotion expectations, Walgreens is on a very different corner.
The merger-and-acquisition activity — from Rite Aid to Amerisource Bergen in the United States and an imminent launch in South Korea with the Shinsegae Group to shopping for other opportunities — all points to an aggressive growth agenda. More than once, official WBA financial documents have stated “paid for out of cash flow.” Connections in the United Kingdom confirm that the focus on cash is real and a part of recent trade promotion negotiations.
At the store level, the 2016 cycles of category reviews have introduced a whole new world. The continuous three-for-two price promotions, tougher margin requirements and a revamped circular are well established. The Boots U.K. playbook also includes significant front-line staff training, and it’s training with real incentives for in-store employees. If you don’t know training content, your job is in jeopardy. It’s just a matter of time before that arrives in Chicago.
Nowhere is the new global Walgreens better reflected than in its North American leader, Alex Gourlay, a Glasgow native and the newly named chairman of the National Association of Chain Drug Stores. Just five years ago, it would have been hard to imagine a Scottish pharmacist who started at age 16 in a U.K. Boots would come to head Walgreens and the most important U.S. drug store trade association. Today, that’s reality. Gourlay’s humble beginnings in the business are refreshing. “I used to [work in] the stockroom, mop floors [and] clean up after the drunks,” he said.
Walgreens used to be at the corner of happy and healthy. Walgreens Boots Alliance is on the corner of global and growing. The old neighborhood has really changed.
Ed Rowland, is a Drug Store News contributing editor covering global issues. As the principal of Rowland Global, he believes in the promise of global business and supports companies in their strategy, tactics and execution of international growth initiatives.
Weis Markets reports Q1 sales increase of 15.4%
SUNBURY, Pa. — Weis Markets earlier this week reported a sales increase of 15.4% to $852.2 million in the first quarter. Comparable store sales, adjusting for the New Year's and Easter holiday shift in 2017, increased 1.1%, the company reported, representing the grocer's 12th consecutive quarter of increased comparable store sales.
During the 13-week period ended April 1, net income declined 41.2% to $11.8 million while earnings per share totaled $0.44 compared to $0.75 in 2016.
"Our net income was impacted by the Easter and New Year holiday shift compared to 2016, a mild winter and overall price deflation," stated Jonathan Weis, Weis Markets chairman and CEO. "We also continued to make significant investments in our pricing and promotional programs throughout our seven state market area."
CDC: Hepatitis C infections nearly tripled from 2010 to 2015
WASHINGTON — Hepatitis C infections spiked by 294% during the 2010-2015 time period, with the highest rates among young persons who inject drugs, according to Centers for Disease Control data released Friday.
According to the CDC, Hepatitis C is the most viral form of hepatitis, and in 2013, accounted for approximately 19,000 deaths per year, a number that was greater than that of 60 other nationally notifiable infectious diseases combined.
The CDC also cited two separate reports, one of which that states only three states had comprehensive laws providing full access to Hepatitis C preventive and treatment services for persons who inject drugs. The second report estimates rates of Hepatitis C infection among pregnant women in the United States, concluding Hepatitis C rates nearly doubled during from 2009 to 2014.
The CDC released in info in advance of National Hepatitis Testing Day on May 19, “to emphasize the importance of testing persons at risk for hepatitis B virus and hepatitis C virus infections, most of whom are unaware of their infection status.”
For more information, click here.